Tyrosine Kinase Inhibitor-induced cardiotoxicity in hiPSC derived cardiomyocytes - pilot dataset (qPCR validation)

To define molecular network markers of tyrosine kinase inhibitor-induced cardiotoxicity, we treated human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) with one of four tyrosine kinase inhibitors displaying a range of mild to severe effects on heart function (Erlotinib, Lapatinib, Sorafenib, or Sunitinib) or vehicle control (DMSO). We performed 3 different treatments for each drug, including two doses (3.16 and 10 µM) at 24 hours and the lower dose (3.16 µM) at 72h. Gene expression changes were assessed at the cell population level using qPCR. This is a validation dataset for RNA-seq HMS-LINCS Dataset #20324.